Effects of a cardiotoxin from Naja naja kaouthia venom on skeletal muscle: involvement of calcium-induced calcium release, sodium ion currents and phospholipases A2 and C.
Snake venom cardiotoxin (CTX) fractions induce contractures of skeletal muscle and hemolysis of red blood cells. The fractions also contain trace amounts of venom-derived phospholipase A2 (PLA2) contamination and activate tissue phospholipase C (PLC) activity. The present study examines the mechanisms of action of a CTX fraction from Naja naja kaouthia venom in skeletal muscle. Sphingosine competitively antagonized CTX-induced red blood cell hemolysis, but not skeletal muscle contractures. CTX rapidly lowered the threshold for Ca(2+)-induced Ca2+ release in heavy sarcoplasmic reticulum fractions, as monitored with arsenazo III. There was also a slower time-dependent reduction of Na+ currents, as assessed by whole cell patch-clamp techniques. The CTX fractions elevated levels of free fatty acids and diacylglycerol for 2 hr in primary cultures of human skeletal muscle by a combined action of venom-derived PLA2 contamination in the fraction and activation of endogenous PLC activity. The activation of tissue PLC activity could be readily distinguished from the contribution of the venom PLA2 by p-bromophenacyl bromide treatment of CTX fractions. The mechanism of action involved in contractures of skeletal muscle appears to be related to the immediate and specific effect of CTX (Ca2+ release by the sarcoplasmic reticulum), while the mechanisms involved in hemolysis of red blood cells and decreased Na+ currents in skeletal muscle most likely relate to long-term effects on lipid metabolism.
Fletcher
J E
JE
Department of Anesthesiology, Hahnemann University, Philadelphia, PA 19102-1192.
Jiang
M S
MS
Gong
Q H
QH
Yudkowsky
M L
ML
Wieland
S J
SJ
D000818:Animals; D002118:Calcium / Q000378:metabolism* / Q000494:pharmacology; D002478:Cells, Cultured; D004179:Cobra Cardiotoxin Proteins / Q000032:analysis / Q000494:pharmacology*; D004912:Erythrocytes / Q000187:drug effects; D006461:Hemolysis / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D050356:Lipid Metabolism; D051379:Mice; D009119:Muscle Contraction / Q000187:drug effects; D009132:Muscles / Q000187:drug effects*; D010741:Phospholipases A / Q000032:analysis / Q000633:toxicity*; D054467:Phospholipases A2; D011112:Polymyxin B / Q000494:pharmacology; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D015222:Sodium Channels / Q000187:drug effects*; D013110:Sphingosine / Q000494:pharmacology; D010738:Type C Phospholipases / Q000032:analysis / Q000633:toxicity*
D004179:Cobra Cardiotoxin Proteins; D015222:Sodium Channels; D010741:Phospholipases A; D054467:Phospholipases A2; D010738:Type C Phospholipases; D011112:Polymyxin B; D013110:Sphingosine; D002118:Calcium